HCA HCA Healthcare (HCA) Insider Trading, Ownership & Congress Trades
Healthcare Services · Services-general medical & surgical hospitals, nec · CIK 0000860730
Congress · 1
Insider buyers, 180 days
0
Funds added, last quarter
580
13F, latest reported quarter
What the filings say about HCA
Congress, 1 year
1 bought · 0 sold
Latest: purchase, 2026-06-17
HCA Healthcare insider trades (Form 4)
Form 4 buys and sells (codes P and S). Grants, option exercises
and conversions excluded.
No insider purchases or sales are on record for HCA Healthcare, Inc. in the period covered. Source: SEC Form 4 filings, as of 2026-10-28.
Insider
Filed
Shares
Value
Since filing
Context
- 2 earlier Form 4 trades (code P or S) here by this insider (1 buy, 1 sale), the last on Nov 5, 2025.
- The trade is 19.1% of the 8,853 shares held after it.
- 4 other insiders sold within 30 days.
- 580 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: EVP & Chief Legal & Admin Off. McAlevey Michael R sold about $903.5K of HCA on Feb 18, 2026; 4 other insiders sold within 30 days and 580 funds added in the latest 13F quarter.Context
- 4 earlier Form 4 trades (code P or S) here by this insider (4 sales), the last on Jul 29, 2024.
- The trade is 9.0% of the 44,379 shares held after it.
- 4 other insiders sold within 30 days.
- 580 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: SVP & Controller Wyatt Christopher F. sold about $2.0M of HCA on Feb 11, 2026; 4 other insiders sold within 30 days and 580 funds added in the latest 13F quarter.Context
- 4 earlier Form 4 trades (code P or S) here by this insider (4 sales), the last on Feb 14, 2025.
- The trade is 33.4% of the 11,993 shares held after it.
- 4 other insiders sold within 30 days.
- 580 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: SVP & Chief Human Res. Officer Berres Jennifer sold about $2.1M of HCA on Feb 11, 2026; 4 other insiders sold within 30 days and 580 funds added in the latest 13F quarter.Context
- 4 earlier Form 4 trades (code P or S) here by this insider (4 sales), the last on Feb 14, 2025.
- The trade is 25.1% of the 16,003 shares held after it.
- 4 other insiders sold within 30 days.
- 580 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: SVP & Chief Human Res. Officer Berres Jennifer sold about $2.0M of HCA on Feb 11, 2026; 4 other insiders sold within 30 days and 580 funds added in the latest 13F quarter.Context
- 3 earlier Form 4 trades (code P or S) here by this insider (3 sales), the last on Nov 2, 2021.
- The trade is 24.3% of the 60,437 shares held after it.
- 4 other insiders sold within 30 days.
- 580 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: CEO HAZEN SAMUEL N sold about $7.4M of HCA on Feb 3, 2026, the largest insider sale at the company since 2023; 4 other insiders sold within 30 days and 580 funds added in the latest 13F quarter.140 transactions on record
Since filing: total return from the first close after the filing to the latest close, dividend-adjusted. Not a forecast.
Context lines are counts over the filings above and returns from our own price history, never a price level. Not investment advice.
Seven facts, ranked against the sector ·
Rank is not a forecast
Insiders
no insider buys or sells on file
Congress
1 member bought in the last year
the lowest in Healthcare Services
Funds
580 funds bought in last quarter
the highest in Healthcare Services
Revenue
+7.1% year over year
below 59% of Healthcare Services
Margin
9.0% net margin
more than 86% of Healthcare Services
Buybacks
$1.6B repurchased, FY to 2026-03-31
the highest in Healthcare Services
Short interest
3.4% of the float short (float per yahoo 2026-10-26) · 3.1 days to cover · settled 2026-09-30
below 61% of Healthcare Services
What changed in the last 30 days
Nothing new filed in the last 30 days
Watch HCA
A free account keeps a watchlist and can send one email a day when insiders, funds or Congress file on the names in it. No password and no card.
The year, with the filings on it
Total return over 12 months. Each marker is a filing; hover or tap one for the detail.
+6.2%12M
Insider sell13D/G stake
Indexed to 100, dividend-adjusted, not a price chart.
When a name files heavily, the largest trades are drawn first.
Who owns HCA: institutional holders (13F)
13F holdings, latest reported quarter
13,003,600 sh
$5.1B
10,141,708 sh
$4.0B
8,828,287 sh
$3.4B
7,469,035 sh
$2.9B
6,591,130 sh
$2.6B
Congress trades in HCA
STOCK Act disclosures, US House only, filed up to 45 days after the trade
Bought 2026-06-17 · disclosed 39 days later
$1,001 - $15,000
Sold 2025-09-11 · disclosed 41 days later
$1,001 - $15,000
Bought 2025-08-19 · disclosed 24 days later
$1,001 - $15,000
Bought 2025-05-15 · disclosed 43 days later
$1,001 - $15,000
Sold 2025-04-07 · disclosed 37 days later
$1,001 - $15,000
Activist and 5% holders (13D/13G)
13D: intends to influence · 13G: passive
Frisco Holding II
Activist 13D · 2026-02-10
17.4%
Hercules Holding II
Activist 13D · 2026-02-10
15.5%
Thomas F. Frist, Jr.
Activist 13D · 2026-02-10
31.6%
Thomas F. Frist III
Activist 13D · 2026-02-10
31.3%
William R. Frist
Activist 13D · 2026-02-10
31.5%
HCA planned insider sales (Form 144)
No planned-sale notices
No insider has filed to sell. Watch this after a run-up.
HCA mutual fund holders (N-PORT)
Funds ranked by the share of their own portfolio in this stock (N-PORT).
Pacer US Cash Cows Growth ETF
$6.7M position · as of 2026-07-31
5.1%
SMI 3Fourteen Full-Cycle Trend ETF
$12.2M position · as of 2026-06-30
5.0%
First Eagle Rising Dividend Fund
$21.8M position · as of 2026-07-31
4.6%
iShares U.S. Healthcare Providers ETF
$52.9M position · as of 2026-06-30
4.5%
Catalyst/Lyons Tactical Allocation Fund
$667.5K position · as of 2026-06-30
3.9%
God Bless America ETF
$3.5M position · as of 2026-05-31
3.6%
SEC N-PORT, monthly, about 60 days late · funds ≥ $10M ·
% is the share of the fund's own portfolio
Corporate PAC
The company's PAC: committee totals only, never individual donors (FEC).
Hca Healthcare, Inc. Good Government Fund
Cycle 2026 · $401K spent
$346.2K
Federal Election Commission, matched by the PAC's connected organisation
Executive pay vs shareholder return · Hazen
CEO pay, headline and as actually paid, against the company's
return and its chosen peers' (DEF 14A).
FY
CEO total
Actually paid
Other execs, avg
TSR
Peer TSR
2025
$26.5M
$78.2M
$8.2M
+196%
+48%
2024
$23.8M
$40.1M
$6.1M
+89%
+29%
2023
$21.3M
$23.6M
$6.9M
+69%
+26%
2022
$14.6M
$9.6M
$5.2M
+49%
+24%
2021
$20.6M
$84.6M
$6.0M
+58%
+26%
Tagged by the company under SEC Item 402(v). Returns are
cumulative from the start of the disclosure period. Green where the company beat its own peer group.
Live price
Daily candles from TradingView, under their licence. No filings marked.
Why this name is on the desk
The complete filing record, in one place.
The record shows 580 funds added last quarter, 1 House member(s) bought in 12 months, disclosed weeks after the trade. Each figure is a federal filing, dated the day it went public.
HCA financials
Revenue growth
+7.1%
XBRL, annual
Net margin
9.0%
Ratios from the company's XBRL filings, latest filings
Revenue, TTM
$76.4B
four quarters, 2025-04-01 to 2026-03-31
Revenue, TTM HCA
| FY Dec 2025 | $75.6B |
| FY Dec 2024 | $70.6B |
| FY Dec 2023 | $65.0B |
| FY Dec 2022 | $60.2B |
| FY Dec 2021 | $58.8B |
| Mar 2026 | $19.1B |
| Dec 2025 | $19.5B |
| Sep 2025 | $19.2B |
| Jun 2025 | $18.6B |
| Mar 2025 | $18.3B |
| Dec 2024 | $18.3B |
| Sep 2024 | $17.5B |
| Jun 2024 | $17.5B |
At each fiscal year end
Single quarter
Net margin, TTM
+8.9%
net income over revenue, 2025-04-01 to 2026-03-31
Net margin, TTM HCA
| FY Dec 2025 | +9.0% |
| FY Dec 2024 | +8.2% |
| FY Dec 2023 | +8.1% |
| FY Dec 2022 | +9.4% |
| FY Dec 2021 | +11.8% |
| Mar 2026 | +8.5% |
| Dec 2025 | +9.6% |
| Sep 2025 | +8.6% |
| Jun 2025 | +8.9% |
| Mar 2025 | +8.8% |
| Dec 2024 | +7.9% |
| Sep 2024 | +7.3% |
| Jun 2024 | +8.4% |
At each fiscal year end
Single quarter
Free cash flow, TTM
$7.9B
operating cash flow minus capex, 2025-04-01 to 2026-03-31
Free cash flow, TTM HCA
| FY Dec 2025 | $7.7B |
| FY Dec 2024 | $5.6B |
| FY Dec 2023 | $4.7B |
| FY Dec 2022 | $4.1B |
| FY Dec 2021 | $5.4B |
| Mar 2026 | $895.0M |
| Dec 2025 | $870.0M |
| Sep 2025 | $3.1B |
| Jun 2025 | $3.0B |
| Mar 2025 | $660.0M |
| Dec 2024 | $1.3B |
| Sep 2024 | $2.3B |
| Jun 2024 | $690.0M |
At each fiscal year end
Single quarter
Debt to equity
n/a
equity is zero or negative, the ratio has no meaning
Debt to equity HCA
| FY Dec 2025 | n/a |
| FY Dec 2024 | n/a |
| FY Dec 2023 | n/a |
| FY Dec 2022 | n/a |
| FY Dec 2021 | n/a |
| Mar 2026 | n/a |
| Dec 2025 | n/a |
| Sep 2025 | n/a |
| Jun 2025 | n/a |
| Mar 2025 | n/a |
| Dec 2024 | n/a |
| Sep 2024 | n/a |
| Jun 2024 | n/a |
At each fiscal year end
Trailing four quarters at each quarter end
Cash flow to debt
0.27x
TTM operating cash flow over long-term 2026-03-31 plus current 2026-03-31
Cash flow to debt HCA
| FY Dec 2025 | 0.27x |
| FY Dec 2024 | 0.24x |
| FY Dec 2023 | 0.24x |
| FY Dec 2022 | 0.22x |
| FY Dec 2021 | 0.26x |
| Mar 2026 | 0.27x |
| Dec 2025 | 0.27x |
| Sep 2025 | 0.29x |
| Jun 2025 | 0.27x |
| Mar 2025 | 0.22x |
| Dec 2024 | 0.24x |
| Sep 2024 | 0.25x |
| Jun 2024 | 0.23x |
At each fiscal year end
Trailing four quarters at each quarter end
Return on equity
n/a
average equity is zero or negative
Return on equity HCA
| FY Dec 2025 | n/a |
| FY Dec 2024 | n/a |
| FY Dec 2023 | n/a |
| FY Dec 2022 | n/a |
| FY Dec 2021 | n/a |
| Mar 2026 | n/a |
| Dec 2025 | n/a |
| Sep 2025 | n/a |
| Jun 2025 | n/a |
| Mar 2025 | n/a |
| Dec 2024 | n/a |
| Sep 2024 | n/a |
| Jun 2024 | n/a |
At each fiscal year end
Trailing four quarters at each quarter end
Return on assets
+11.2%
TTM net income over average of 2025-03-31 and 2026-03-31
Return on assets HCA
| FY Dec 2025 | +11.3% |
| FY Dec 2024 | +10.0% |
| FY Dec 2023 | +9.6% |
| FY Dec 2022 | +10.9% |
| FY Dec 2021 | +14.2% |
| Mar 2026 | +11.2% |
| Dec 2025 | +11.3% |
| Sep 2025 | +10.6% |
| Jun 2025 | +10.2% |
| Mar 2025 | +9.9% |
| Dec 2024 | +10.0% |
| Sep 2024 | +10.4% |
| Jun 2024 | +10.3% |
At each fiscal year end
Trailing four quarters at each quarter end
Return on invested capital
n/a
fewer than four consecutive quarters of operating income
Return on invested capital HCA
| FY Dec 2025 | n/a |
| FY Dec 2024 | n/a |
| FY Dec 2023 | n/a |
| FY Dec 2022 | n/a |
| FY Dec 2021 | n/a |
| Mar 2026 | n/a |
| Dec 2025 | n/a |
| Sep 2025 | n/a |
| Jun 2025 | n/a |
| Mar 2025 | n/a |
| Dec 2024 | n/a |
| Sep 2024 | n/a |
| Jun 2024 | n/a |
At each fiscal year end
Trailing four quarters at each quarter end
Return on capital employed
n/a
fewer than four consecutive quarters of operating income
Return on capital employed HCA
| FY Dec 2025 | n/a |
| FY Dec 2024 | n/a |
| FY Dec 2023 | n/a |
| FY Dec 2022 | n/a |
| FY Dec 2021 | n/a |
| Mar 2026 | n/a |
| Dec 2025 | n/a |
| Sep 2025 | n/a |
| Jun 2025 | n/a |
| Mar 2025 | n/a |
| Dec 2024 | n/a |
| Sep 2024 | n/a |
| Jun 2024 | n/a |
At each fiscal year end
Trailing four quarters at each quarter end
P/E, trailing
16.02x
close 2026-10-26 over four quarters of diluted EPS, 2025-04-01 to 2026-03-31
P/E, trailing HCA
| FY Dec 2025 | 16.47x |
| FY Dec 2024 | 13.66x |
| FY Dec 2023 | 14.28x |
| FY Dec 2022 | 12.54x |
| FY Dec 2021 | 12.10x |
| Mar 2026 | 16.30x |
| Dec 2025 | 16.47x |
| Sep 2025 | 16.47x |
| Jun 2025 | 16.10x |
| Mar 2025 | 15.36x |
| Dec 2024 | 13.66x |
| Sep 2024 | 18.27x |
| Jun 2024 | 15.10x |
At each fiscal year end
Trailing four quarters at each quarter end
Enterprise value
$150.3B
market value at close 2026-10-26 on 2026-04-27 shares, plus long-term 2026-03-31 plus current 2026-03-31, minus cash 2026-03-31
Enterprise value HCA
| FY Dec 2025 | $152.0B |
| FY Dec 2024 | $117.1B |
| FY Dec 2023 | $111.1B |
| FY Dec 2022 | $105.0B |
| FY Dec 2021 | $113.0B |
| Mar 2026 | $152.9B |
| Dec 2025 | $152.0B |
| Sep 2025 | $143.2B |
| Jun 2025 | $135.7B |
| Mar 2025 | $129.3B |
| Dec 2024 | $117.1B |
| Sep 2024 | $145.0B |
| Jun 2024 | $124.2B |
At each fiscal year end
Trailing four quarters at each quarter end
FCF yield
+7.7%
TTM free cash flow over market value at close 2026-10-26
FCF yield HCA
| FY Dec 2025 | +7.2% |
| FY Dec 2024 | +7.4% |
| FY Dec 2023 | +6.5% |
| FY Dec 2022 | +6.1% |
| FY Dec 2021 | +6.7% |
| Mar 2026 | +7.5% |
| Dec 2025 | +7.2% |
| Sep 2025 | +8.1% |
| Jun 2025 | +7.9% |
| Mar 2025 | +5.8% |
| Dec 2024 | +7.4% |
| Sep 2024 | +5.6% |
| Jun 2024 | +5.8% |
At each fiscal year end
Trailing four quarters at each quarter end
PEG, trailing
0.55x
P/E over trailing EPS growth of 29%: four quarters to 2026-03-31 against the four to 2025-03-31
PEG, trailing HCA
| FY Dec 2025 | 0.57x |
| FY Dec 2024 | 0.86x |
| FY Dec 2023 | n/a |
| FY Dec 2022 | n/a |
| FY Dec 2021 | 0.13x |
| Mar 2026 | 0.56x |
| Dec 2025 | 0.57x |
| Sep 2025 | 1.01x |
| Jun 2025 | 1.36x |
| Mar 2025 | 1.25x |
| Dec 2024 | 0.86x |
| Sep 2024 | 1.84x |
| Jun 2024 | 2.94x |
At each fiscal year end
Trailing four quarters at each quarter end
Price as of 2026-10-26. Hover or tap a tile for its yearly and quarterly history.
Method
TTM is four consecutive fiscal quarters; Q4 is the year minus nine months when not filed. Returns use the average of opening and closing balances. EBIT is approximated by operating income. PEG uses trailing EPS growth.
Fundamentals
Annual figures from XBRL filings. Pick a past date to see them as known then.
| 2025-12 | 2024-12 | 2023-12 | 2022-12 | |
|---|---|---|---|---|
| Revenue | $75.6B | $70.6B | $65.0B | $60.2B |
| Net income | $6.8B | $5.8B | $5.2B | $5.6B |
| EPS (diluted) | 28.33 | 22.00 | 18.97 | 19.15 |
| Operating cash flow | $12.6B | $10.5B | $9.4B | $8.5B |
| Cash | $1.0B | $1.9B | $935.0M | $908.0M |
| Long-term debt | $41.6B | $38.3B | $37.2B | $37.7B |
| Buybacks | $10.1B | $6.0B | $3.8B | $7.0B |
| Dividends paid | $679.0M | $690.0M | $661.0M | $653.0M |
SEC XBRL, fiscal years, as known on 2026-10-28
HCA Stock Sonar score 4/7 axes
Find similar shapesCompareHCA ranks highest on institutional and government (89th percentile) and financial health (60th), and lowest on risk and compliance (38th), among Healthcare Services peers.
4 of 7 axes scored. Each is a percentile against sector peers (all companies when the sector is thin); higher is better. An unscored axis is unmeasured, not low. How it is scored
HCA filings, in plain words
Have members of Congress traded HCA?
Yes. In the year to 2026-10-28, 1 House member disclosed buying HCA and 0 House members disclosed selling it; the latest on record is a purchase by Jared Moskowitz dated 2026-06-17.
Read the full summary
In the year to 2026-10-28, 1 member of Congress disclosed buying HCA and 0 members disclosed selling it; the latest on record is a purchase by Jared Moskowitz dated 2026-06-17. The latest 5% ownership filing is a 13D by Frisco Holding II, filed 2026-02-10, for 17.4% of the class. Each figure is counted from SEC and House filings as of 2026-10-28, dated the day the filing was made public.
Explore insider trading and ownership data
Every company we track, ranked by each kind of filing
